Sustainability · Energy
Kolon Industries Begins Production of Bio-Based Medical Plastic
South Korean materials firm claims first commercial-scale polyoxymethylene made with renewable methanol, targeting medical device supply chains

KEY TAKEAWAYS
- ·Kolon Industries has started commercial production of Kocetal ECO-E, a polyoxymethylene resin made from renewable methanol, claiming a global first for bio-based POM at scale.
- ·The material targets medical-device manufacturers facing tighter carbon-disclosure rules in the EU and California, where scope-three emissions now influence procurement decisions.
- ·Renewable methanol supply remains constrained at under 200,000 tons annually, commanding a 20 to 40 percent price premium over conventional methanol.
A New Feedstock Route for High-Performance Polymers
Kolon Industries announced Wednesday it has begun commercial-scale manufacturing of Kocetal ECO-E, a polyoxymethylene resin formulated for medical-device applications, according to the company. The material represents the first POM produced from methanol sourced through renewable-energy pathways, replacing the fossil-derived feedstock that has powered the global engineering-plastics industry for decades.
Polyoxymethylene occupies a specialized niche in precision manufacturing. Its low-friction surface, dimensional stability under load, and resistance to wear make it the material of choice for gears, bearings, surgical instrument housings, and drug-delivery mechanisms. Until now, every kilogram of POM on the market traced its carbon ancestry to natural gas or coal.
Kolon's process substitutes renewable methanol - synthesized using electricity from wind, solar, or hydropower - at the front end of the polymer chain. The swap preserves the mechanical properties engineers depend on while cutting embedded carbon across the product's life cycle, the company said.
Medical Devices as the Beachhead Market
The initial production run targets medical-device manufacturers, a segment where regulatory validation cycles are long but material traceability and sustainability disclosures are increasingly mandatory. Hospital procurement teams in the European Union and California now factor scope-three emissions into tender evaluations, and device makers face growing pressure to document the carbon intensity of components.
Kolon Industries has not disclosed production volumes, pricing, or the identity of launch customers. The company operates POM capacity in Gumi, South Korea, where it also produces aramid fiber and industrial films. Expanding bio-based feedstock availability in Northeast Asia remains a bottleneck; renewable methanol today commands a price premium of 20 to 40 percent over conventional methanol, depending on contract terms and certification requirements.
Carbon Accounting and the Materials Transition
Engineering plastics account for a small share of total polymer demand - roughly 3 percent by volume - but they punch above their weight in value and emissions intensity. POM production is energy-intensive, and the material's use in long-life applications means carbon payback periods stretch across years.
Kolon's approach mirrors strategies unfolding in Europe, where Clariant and Neste have piloted renewable feedstocks for polyamides, and in Japan, where Mitsubishi Chemical is scaling bio-attributed polycarbonate. The common thread: substituting the feedstock rather than redesigning the polymer, which allows drop-in compatibility with existing molds, processing equipment, and regulatory dossiers.
The challenge lies in securing certified renewable methanol at scale. Global production today sits below 200,000 tons per year, a fraction of the 110 million tons of conventional methanol consumed annually. Most renewable methanol comes from biomass gasification or carbon-capture projects in Scandinavia and China, with long-term off-take agreements already subscribed by chemical majors.
What Comes Next
Kolon has signaled plans to extend the ECO-E line beyond medical grades, though it has not specified timelines or target sectors. Automotive interiors, electronics housings, and consumer appliances all consume POM, but each brings distinct certification and cost tolerance.
The medical launch buys time to refine supply economics and build a reference base. If device makers validate performance and regulators accept the material's equivalence to incumbent resins, Kolon will have a proof point for broader commercialization. If renewable methanol costs fall - through policy support, electrolyzer scale-up, or direct-air-capture advances - the business case strengthens.
For now, Kocetal ECO-E remains a small batch in a vast petrochemical system. Its significance lies not in volume but in direction: a signal that even high-performance polymers, long tethered to fossil inputs, can begin the pivot toward bio-based and circular feedstocks.
RELATED STORIES
Spot something wrong? Email editor@briefasia.com. We log every correction publicly.



